Brelor is a generic antiplatelet drug called P2Y11 inhibitor.
Indications for Brelor include prevention and reduction of the risk of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome, and prevention of stent clotting in patients undergoing angioplasty.
Since the inalienable right of every Iranian patient is to consume high quality medicine, in order to achieve this goal and to support patients, Kimiara Company has produced its Ticagrelor under the Brelor brand, according to the highest international standards.
API and formulations of Ticagrelor is produced by the most powerful API supplier in the world called MSN. The Ticagrelor product line in this company is approved by the US Food and Drug Administration and the European GMP. MSN company is ranked first in terms of the number of drug cases in the US and is one of the top 17 generic pharmaceutical companies in the world.
Another indicator of Brelor quality is the efficacy and safety of this drug similar to its original brand, Astrazeneca Brillinta, which has been proven in bioequivalence studies. Citing the quality of API, formulation, production line of this drug as well as bioequivalence studies, Brelor with the highest quality is a reliable alternative to its main brand in Iran.